Copyright
©The Author(s) 2022.
World J Hepatol. Sep 27, 2022; 14(9): 1778-1789
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1778
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1778
Table 1 Clinicopathological characteristics and univariate analysis of 1106 patients
| n (%) | P value | |
| Preoperative variables | ||
| Age (yr) | 0.202 | |
| ≤ 55 | 436 (39) | |
| > 55 | 670 (61) | |
| Sex | 0.098 | |
| Male | 863 (78) | |
| Female | 243 (22) | |
| Viral hepatitis | 0.111 | |
| No viral hepatitis | 185 (17) | |
| Hepatitis B or C or B + C | 921 (83) | |
| Child Class | 0.964 | |
| A/B | 1099 (99) | |
| C | 7 (1) | |
| Platelet count (103/μL) | 0.003 | |
| < 100 | 124 (11) | |
| ≥ 100 | 982 (89) | |
| Total bilirubin (mg/dL) | 0.032 | |
| ≤ 1.3 | 1010 (91) | |
| > 1.3 | 96 (9) | |
| PT-INR | 0.053 | |
| ≤ 1.2 | 1004 (91) | |
| > 1.2 | 102 (9) | |
| Albumin (g/dL) | 0.001 | |
| < 3.5 | 86 (8) | |
| ≥ 3.5 | 1020 (92) | |
| AFP (ng/mL) | 0.116 | |
| < 200 | 785 (71) | |
| ≥ 200 | 321 (29) | |
| ICG (%) | < 0.0001 | |
| ≤ 10 | 748 (68) | |
| > 10 | 358 (32) | |
| Multiplicity | < 0.0001 | |
| Solitary | 852 (77) | |
| Multiple | 254 (23) | |
| Radiologic TTV (cm3) | < 0.0001 | |
| mean ± SD | 113.06 ± 237.13 | |
| ≤ 32.0 | 645 (58) | |
| > 32.0 | 461 (42) | |
| Postoperative variables | ||
| Resection margin (cm) | 0.082 | |
| ≤ 1.0 | 817 (74) | |
| > 1.0 | 249 (23) | |
| Liver cirrhosis | 0.001 | |
| No | 585 (53) | |
| Yes | 521 (47) | |
| Tumor rupture | 0.004 | |
| No | 1076 (97) | |
| Yes | 30 (3) | |
| Edmondson-Steiner grade | < 0.0001 | |
| I/II | 682 (62) | |
| III/IV | 424 (38) | |
| Capsule | 0.789 | |
| No | 192 (17) | |
| Yes | 914 (83) | |
| Microvascular invasion | < 0.0001 | |
| No | 786 (71) | |
| Yes | 320 (29) | |
| Pathologic TTV (cm3) | < 0.0001 | |
| mean ± SD | 131.59 ± 293.81 | |
| ≤ 32.8 | 652 (59) | |
| > 32.8 | 454 (41) | |
Table 2 Univariate and multivariate analysis of prognostic factors
| UV P value | HR | 95%CI | MV P value | |
| Platelet count (103/μL) | 0.003 | 1.192-1.882 | 0.001 | |
| < 100 | 1.498 | |||
| ≥ 100 | 1 | |||
| Total bilirubin (mg/dL) | 0.032 | - | ||
| ≤ 1.3 | ||||
| > 1.3 | ||||
| Albumin (g/dL) | 0.001 | 1.121-1.907 | 0.005 | |
| < 3.5 | 1.462 | |||
| ≥ 3.5 | 1 | |||
| ICG (%) | < 0.0001 | 1.104-1.507 | 0.001 | |
| ≤ 10 | 1 | |||
| > 10 | 1.289 | |||
| Multiplicity | < 0.0001 | 1.422-2.019 | < 0.0001 | |
| Solitary | 1 | |||
| Multiple | 1.694 | |||
| Radiologic TTV (cm3) | < 0.0001 | 1.501-2.024 | < 0.0001 | |
| ≤ 32.0 | 1 | |||
| > 32.0 | 1.743 |
Table 3 Point values for risk groups according to the Cox regression model
| Predictor variables | Regression coefficients (β) | Categories | Reference value (W) | Β (W-WREF) | Points = β (W-WREF)/constant B |
| Platelet count (103/μL) | 0.4039 | < 100000 | 1 | 0.4039 | 2 |
| ≥ 100000 | 0 (WREF) | 0 | 0 | ||
| Albumin (g/dL) | 0.3805 | < 3.5 | 1 | 0.3805 | 1 |
| ≥ 3.5 | 0 (WREF) | 0 | 0 | ||
| ICG (%) | 0.2544 | ≤ 10 | 0 (WREF) | 0 | 0 |
| > 10 | 1 | 0.25441 | 1 | ||
| Multiplicity | 0.5274 | Solitary | 0 (WREF) | 0 | 0 |
| Multiple | 1 | 0.5274 | 2 | ||
| Radiologic TTV (cm3) | 0.5558 | ≤ 32.0 | 0 (WREF) | 0 | 0 |
| > 32.0 | 1 | 0.5558 | 2 |
Table 4 Discrimination measures and hazard ratios evaluated among four scoring systems
| Scoring system | CGMH | AJCC 8th edition | Tokyo | Taipei | ||||||||||||
| Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | |||||||||
| Measures of discrimination | ||||||||||||||||
| Harrell’s CH | 0.617 | 0.01 | 0.617 | 0.01 | 0.613 | 0.011 | 0.562 | 0.01 | ||||||||
| Gonen and Heller’s CGH | 0.599 | 0.009 | 0.586 | 0.009 | 0.587 | 0.01 | 539 | 0.009 | ||||||||
| Royston & Sauerbrei’s D | 0.672 | 0.066 | 0.577 | 0.065 | 0.589 | 0.066 | 0.292 | 0.067 | ||||||||
| Prognostic scoring system | HR | 95%CI of HR | P value | HR | 95%CI of HR | P value | HR | 95%CI of HR | P value | HR | 95%CI of HR | P value | ||||
| CGMH: Low1 | 1 | 1 | 1 | 1 | ||||||||||||
| Intermediate, high | 1.81 | 1.50-2.19 | < 0.0001 | 1.35 | 1.08-1.69 | 0.009 | 1.55 | 1.04-2.29 | 0.03 | 1.21 | 1.01-1.45 | 0.039 | ||||
| AJCC 8th edition: | 2.74 | 2.25-3.34 | < 0.0001 | 1.69 | 1.29-2.21 | < 0.001 | 1.7 | 1.16-2.49 | 0.007 | 1.43 | 1.08-1.88 | 0.012 | ||||
| IA1, IB, II, IIIA, IIIB | 2.08 | 1.57-2.76 | < 0.0001 | 2.64 | 1.76-3.96 | < 0.0001 | 1.79 | 1.31-2.44 | < 0.001 | |||||||
| Tokyo: 01, 1, 2, 3, 4, 5 | 3.15 | 2.41-4.12 | < 0.0001 | 4.14 | 2.70-6.36 | < 0.0001 | 1.26 | 0.97-1.64 | 0.079 | |||||||
| Taipei: 01, 1, 2, 3, 4 | 4.1 | 2.54-6.63 | < 0.0001 | |||||||||||||
Table 5 Performance of prognostic scoring systems
| Prognostic scoring system | Homogeneity | Discriminatory ability | Akaike information criterion |
| Likelihood ratio χ2 | Linear trend χ2 | ||
| CGMH | 106.05 | 106.48 | 9305.48 |
| AJCC 8th | 81.53 | 94.16 | 9336.01 |
| Tokyo | 93.02 | 109.45 | 9324.52 |
| Taipei | 18.76 | 20.41 | 9396.77 |
- Citation: Lai Y, Lee JC, Hung HC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Kao CY, Lee WC. Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections. World J Hepatol 2022; 14(9): 1778-1789
- URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1778.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i9.1778
